Abstract
The family of α2-adrenergic receptors (α2-ARs) comprises three subtypes which are each endowed with specific functions. α2-agonists and α2-antagonists are part of the clinician armamentarium since several decades; however, none of the compounds so far available is subtype selective. For long, clonidine and yohimbine have been used for the treatment of hypertension and impotence respectively, but both have been superseded by newer drugs. This review attempts, by a comprehensive analysis of the literature, to cover the present clinical use and the potential therapeutic interest of α2-agonists or antagonists. From the clinical data, it is concluded that, with the exception of a few particular situations, α2-agonists are only of limited utility as a monotherapy. By contrast, they offer several powerful advantages when used in adjunctive therapy. In perioperative settings, α2-agonists are extremely valuable adjuncts to anesthetics and analgesics for the induction of anxiolysis, maintenance of sedation, management of pain and prevention of shivering. In the ophthalmic clinic, they are used to lower intra-ocular pressure during laser surgery of the eye. As a daily medication, α2-agonists are also of interest for the treatment of glaucoma, muscle spasticity, opiate withdrawal, and behavior disorders. The a2-antagonists are useful antidotes for reversing the threatening effects of agonist overdose, but currently there are very few indications. New applications are under investigation, and new molecules with more refined subtypeselectivity may emerge, so the clinical utility of both α2-agonists and antagonists will undoubtedly expand in the future.
Keywords: Attention-deficit hyperactivity, Primary open-angle glaucoma, Hypertension, Withdrawal syndrome, Muscle Spasticity
Current Topics in Medicinal Chemistry
Title: Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Volume: 7 Issue: 2
Author(s): Pierre-Antoine Crassous, Colette Denis, Herve Paris and Jean Michel Senard
Affiliation:
Keywords: Attention-deficit hyperactivity, Primary open-angle glaucoma, Hypertension, Withdrawal syndrome, Muscle Spasticity
Abstract: The family of α2-adrenergic receptors (α2-ARs) comprises three subtypes which are each endowed with specific functions. α2-agonists and α2-antagonists are part of the clinician armamentarium since several decades; however, none of the compounds so far available is subtype selective. For long, clonidine and yohimbine have been used for the treatment of hypertension and impotence respectively, but both have been superseded by newer drugs. This review attempts, by a comprehensive analysis of the literature, to cover the present clinical use and the potential therapeutic interest of α2-agonists or antagonists. From the clinical data, it is concluded that, with the exception of a few particular situations, α2-agonists are only of limited utility as a monotherapy. By contrast, they offer several powerful advantages when used in adjunctive therapy. In perioperative settings, α2-agonists are extremely valuable adjuncts to anesthetics and analgesics for the induction of anxiolysis, maintenance of sedation, management of pain and prevention of shivering. In the ophthalmic clinic, they are used to lower intra-ocular pressure during laser surgery of the eye. As a daily medication, α2-agonists are also of interest for the treatment of glaucoma, muscle spasticity, opiate withdrawal, and behavior disorders. The a2-antagonists are useful antidotes for reversing the threatening effects of agonist overdose, but currently there are very few indications. New applications are under investigation, and new molecules with more refined subtypeselectivity may emerge, so the clinical utility of both α2-agonists and antagonists will undoubtedly expand in the future.
Export Options
About this article
Cite this article as:
Crassous Pierre-Antoine, Denis Colette, Paris Herve and Senard Jean Michel, Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318190
DOI https://dx.doi.org/10.2174/156802607779318190 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design Targets of Anti-glucocorticoid Therapy for Stress-related Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Hypoxia in Endometrial Cancer
Current Pharmaceutical Biotechnology Modulation of Angiotensin II Effects, A Potential Novel Approach to Inflammatory and Immune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Current Traditional Medicine Aging Related Changes in Mixed Basal Saliva Concentration of Sodium, Potassium and Chloride in Healthy Non Medicated Humans
Current Aging Science Relationships between Serotoninergic System and Skin Fibrotic
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Erythropoietin Treatment in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Drug Delivery Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Pomegranate Consumption and Blood Pressure: A Review
Current Pharmaceutical Design Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews Recent Developments in the Synthesis of Cinnoline Derivatives
Mini-Reviews in Organic Chemistry Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry Acute Respiratory Distress Syndrome-Past, Present and Future
Current Respiratory Medicine Reviews